Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Inclusion Criteria:

• Participant is an adult ≥18 years of age.

• Participant has a diagnosis of NF1 based on germline genetic testing or by meeting ≥ 2 the following criteria:

• Family history of NF1

• Six or more light brown ("cafe-au-lait") spots on the skin

• Presence of two or more neurofibromas of any type, or one or more plexiformneurofibromas

• Freckling under the arms or in the groin area

• Two or more pigmented, benign bumps on the eye's iris (Lisch nodules)

• A distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behindthe eye, or dysplasia of long bones, often in the lower leg

• Tumor on the optic nerve that may interfere with vision

• Participant is seeking treatment for cNF.

• Participants must have ≥ 12 paired cNF (6 to be treated without DCD, 6 to be treatedwith DCD) that are visible and measure at least 2 mm in size in the target treatmentarea. The target treatment area must be amenable to both laser treatments andsurveillance with digital and 3D photography. Preferred locations are trunk (back orchest), arms and legs.

• Participant is able and willing to comply with all visit, treatment, and evaluationschedules and requirements.

• Participant is able to understand and provide written informed consent.

• Participant has no concurrent injury or wound in the target area.

Exclusion Criteria:

• Participant cannot give informed consent or adhere to study schedule.

• Participant is Fitzpatrick skin type V-VI.

• Participant is actively tanning during the course of the study.

• For female participants: participant is pregnant.

• Participant has any condition which, in the Investigator's opinion, would make itunsafe (for the participant or study personnel) to treat the participant as part ofthis research study.